{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-044123","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.901654+00:00","generated_at":"2026-05-25T16:51:16.379517+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025","bullets":["FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).","PDUFA target action date set for December 30, 2025.","NDA supported by positive GRACE, GRADIENT, and Phase 2 trial results.","No drug-induced adrenal insufficiency, hypokalemia, or QT prolongation observed in trials.","CEO states relacorilant has potential to become new standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-044123","json":"https://secwatch.observer/filing/0001193125-25-044123.json","markdown":"https://secwatch.observer/filing/0001193125-25-044123.md","text":"https://secwatch.observer/filing/0001193125-25-044123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/0001193125-25-044123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T16:51:16.379517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}